Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaccine business helps Lonza lift 2021 sales outlook

07/23/2021 | 02:04am EDT

* Sales and earnings beat forecasts during H1

* Company raises sales guidance for full year

* Plans to increase capex during H2 to raise production

ZURICH, July 23 (Reuters) - Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year.

The company, which has intensified agreements with vaccine producer Moderna, said sales to the U.S. company had exceeded expectations, although it was also seeing a broad-based improvement in sales of non-coronavirus related products.

"In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters.

Following a 13.3% increase in sales during the first half of 2021, the Basel company said it now expects sales to increase in constant exchange rates towards the mid-teens percentage level this year.

Its previous guidance had been for sales growth in the low double-digit range.

Savitsky said although the increased sales of COVID-19 related products played a role in the upgrade, their impact should not be overstated.

"Covid (products) still represent a relatively small part of our overall sales," he said. "It has an impact, but we see strong momentum across the whole portfolio."

For the first half of the year, Lonza posted sales of 2.54 billion Swiss francs ($2.76 billion), beating analysts' forecasts for 2.47 billion francs.

Core earnings before interest, tax, depreciation and amortisation (EBITDA) rose 13% to 847 million francs, also beating the 787 million francs forecast in a company-gathered poll of analysts.

"All in all, a good set of figures," said Bank Vontobel analyst Sibylle Bischofberger.

Lonza shares, which have outpaced the blue-chip Swiss Market Index by rising 19.4% in 2021, gained 2.1% in early trading.

The company is responding to rising demand by increasing its capital expenditure to 474 million francs in the first half of the year.

More spending was to come in the second half of the year, talking the 2021 capex level to 25% of sales, up from the usual level of around 20%.

Among the investments has been the addition of three extra production lines at the company's plant in Visp, Switzerland, while another line has been added at its site at Geleen in the Netherlands.

Lonza has also hired 1,000 more workers in the first half of the year, and planned to take on another 2,000 in the second half to tackle production log-jams.

"We have solid growth," said Chief Executive Pierre-Alain Ruffieux said "We need to be able to fulfill our obligations in manufacturing." ($1 = 0.9200 Swiss francs)

(Reporting by John Revill; Editing by Shailesh Kuber, Keith Weir and Kim Coghill)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.04% 8845 Delayed Quote.20.77%
CAPRICOR THERAPEUTICS, INC. 4.18% 5.23 Delayed Quote.52.48%
HUMANIGEN, INC. -3.20% 6.36 Delayed Quote.-63.66%
LONZA GROUP AG -2.26% 742.6 Delayed Quote.30.56%
MODERNA, INC. -5.38% 430.14 Delayed Quote.311.74%
All news about LONZA GROUP AG
09/24LONZA : To Manufacture Allarity Therapeutics' Kidney Cancer Candidate Dovitinib
09/23LONZA : Stifel Lifts Price Target on Lonza Group, Maintains Hold Recommendation
09/23Allarity Therapeutics and Lonza Collaborates to Manufacture Dovitinib, a Renal Cell Car..
09/22LONZA : to Invest in Expanding Drug Product Development Network in Switzerland
09/22LONZA : Invests to Expand Drug Product Development and Manufacturing Services in Switzerla..
09/21LONZA : Triumvira Begins Human Trials for T-Cell Cancer Therapy
09/21Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cance..
09/13LONZA : Swiss Parliament Excluded from Federal Council's Vaccine Production Talks With Lon..
08/26GLOBAL MARKETS LIVE : UMG, Delta Air Lines, Shiseido, Qantas, Lonza...
08/26LONZA : CFO to Move to Another Company; Novartis Executive to Take Over
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Sales 2021 5 151 M 5 569 M 5 569 M
Net income 2021 750 M 811 M 811 M
Net cash 2021 314 M 340 M 340 M
P/E ratio 2021 74,0x
Yield 2021 0,41%
Capitalization 55 163 M 59 611 M 59 647 M
EV / Sales 2021 10,6x
EV / Sales 2022 9,39x
Nbr of Employees 14 405
Free-Float 99,7%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 742,60 CHF
Average target price 765,21 CHF
Spread / Average Target 3,05%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG30.56%59 611
MODERNA, INC.311.74%173 624
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353